[O6] Oral Session 6　呼吸器1（分子標的 EGFR, ALK）
【E】

[O6-2] ORCHARD osimertinib + savolitinib interim analysis: PhII platform study in EGFRm NSCLC after progression on osimertinib

^○岡本 勇¹, Yu Helena², Ambrose Helen³, Baik Christina⁴, Cho Byoung Chul⁵, Cocco Emiliano⁶, Goldberg Sarah B⁷, Goldman Jonathan⁸, Kraljevic Silvija³, de Langen Adrianus Johannes⁹, Piotrowska Zofia¹⁰, Pluta Michael¹¹, Maidment Julie¹², Reguart Noemí¹³, Riess Jonathan W¹⁴, Le Xiuning¹⁵ (1.九州大学 呼吸器科, 2.Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, 3.Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK, 4.Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, USA, 5.Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea, 6.Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA, 7.Yale School of Medicine, New Haven, CT, USA, 8.UCLA, Los Angeles, CA, USA, 9.Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 10.Department of Medicine, Massachusetts General Hospital, Boston, MA, USA, 11.Early Oncology, Oncology Statistics, AstraZeneca, Cambridge, UK, 12.Patient Safety Oncology, Chief Medical Office, AstraZeneca, Cambridge, UK, 13.Department of Medical Oncology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain, 14.Internal Medicine – Haematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA, 15.Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA)